These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 935859)
21. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Keyes KA; Mann L; Sherman M; Galbreath E; Schirtzinger L; Ballard D; Chen YF; Iversen P; Teicher BA Cancer Chemother Pharmacol; 2004 Feb; 53(2):133-40. PubMed ID: 14593497 [TBL] [Abstract][Full Text] [Related]
22. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623 [TBL] [Abstract][Full Text] [Related]
23. TNP-470 fails to block the onset of angiogenesis and early tumor establishment in an intravital minimal disease model. Cernaianu G; Frank S; Erbstösser K; Leonhardt S; Cross M; McIvor Z; Scholz G; Dansranjavin T; Celik I; Tannapfel A; Wittekind C; Troebs RB; Rothe K; Bennek J; Hauss J; Witzigmann H Int J Colorectal Dis; 2006 Mar; 21(2):143-54. PubMed ID: 15937694 [TBL] [Abstract][Full Text] [Related]
24. Intratumor microvessel density as a prognostic factor in cancer. Weidner N Am J Pathol; 1995 Jul; 147(1):9-19. PubMed ID: 7541613 [No Abstract] [Full Text] [Related]
25. Tumor-secreted vascular permeability factor/vascular endothelial growth factor influences photosensitizer uptake. Roberts WG; Hasan T Cancer Res; 1993 Jan; 53(1):153-7. PubMed ID: 8416739 [TBL] [Abstract][Full Text] [Related]
26. Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Struyf S; Burdick MD; Peeters E; Van den Broeck K; Dillen C; Proost P; Van Damme J; Strieter RM Cancer Res; 2007 Jun; 67(12):5940-8. PubMed ID: 17575164 [TBL] [Abstract][Full Text] [Related]
27. Demonstration of a protease inhibitor in the cornea. Skoza L; Herp A; Bloomfield SE; Dunn MW Invest Ophthalmol Vis Sci; 1979 Aug; 18(8):827-30. PubMed ID: 222706 [TBL] [Abstract][Full Text] [Related]
28. The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells. He GA; Luo JX; Zhang TY; Hu ZS; Wang FY Biochem Biophys Res Commun; 2004 May; 318(2):354-60. PubMed ID: 15120609 [TBL] [Abstract][Full Text] [Related]
29. Effects of prostaglandin synthesis inhibitors on tumor growth and vascularization. Experimental studies in the rat. Peterson HI Invasion Metastasis; 1983; 3(3):151-9. PubMed ID: 6203870 [TBL] [Abstract][Full Text] [Related]
30. Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumor growth. Erez N; Milyavsky M; Eilam R; Shats I; Goldfinger N; Rotter V Cancer Res; 2003 Dec; 63(24):8777-83. PubMed ID: 14695194 [TBL] [Abstract][Full Text] [Related]
31. Effect of purinergic receptor antagonists suramin and theobromine on tumor-induced angiogenesis in BALB/c mice. Gil M; Skopińska-Rózewska E; Radomska D; Demkow U; Skurzak H; Rochowska M; Beuth J; Roszkowski K Folia Biol (Praha); 1993; 39(2):63-8. PubMed ID: 7504997 [TBL] [Abstract][Full Text] [Related]
33. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Sawaoka H; Tsuji S; Tsujii M; Gunawan ES; Sasaki Y; Kawano S; Hori M Lab Invest; 1999 Dec; 79(12):1469-77. PubMed ID: 10616198 [TBL] [Abstract][Full Text] [Related]
34. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Gee MS; Procopio WN; Makonnen S; Feldman MD; Yeilding NM; Lee WM Am J Pathol; 2003 Jan; 162(1):183-93. PubMed ID: 12507901 [TBL] [Abstract][Full Text] [Related]
35. Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts. Konerding MA; Malkusch W; Klapthor B; van Ackern C; Fait E; Hill SA; Parkins C; Chaplin DJ; Presta M; Denekamp J Br J Cancer; 1999 May; 80(5-6):724-32. PubMed ID: 10360650 [TBL] [Abstract][Full Text] [Related]
36. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. O'Reilly MS EXS; 1997; 79():273-94. PubMed ID: 9002223 [TBL] [Abstract][Full Text] [Related]
37. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Fong TA; Shawver LK; Sun L; Tang C; App H; Powell TJ; Kim YH; Schreck R; Wang X; Risau W; Ullrich A; Hirth KP; McMahon G Cancer Res; 1999 Jan; 59(1):99-106. PubMed ID: 9892193 [TBL] [Abstract][Full Text] [Related]